Neuraxis (NRXS) Change in Accured Expenses (2022 - 2025)
Neuraxis (NRXS) posted Change in Accured Expenses of $536745.0 for Q4 2025, up 288.47% sequentially from $138170.0 in Q3 2025, and up 196.53% YoY from $181007.0 in Q4 2024.
Neuraxis (NRXS) Change in Accured Expenses (2022 - 2025) Analysis & Trends
Neuraxis has reported Change in Accured Expenses for 4 years, with the latest figure at $536745.0 in Q4 2025.
- Quarterly Change in Accured Expenses rose 196.53% year-over-year to $536745.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.1 million (up 14.01% YoY) and the FY2025 annual result came in at $1.1 million, up 14.01% from the prior year.
- Change in Accured Expenses climbed to $536745.0 in Q4 2025 per NRXS's latest filing, from $138170.0 in the prior quarter.
- Over five years, Change in Accured Expenses peaked at $592114.0 in Q2 2024 and troughed at -$755499.0 in Q3 2023.
- A 4-year average of $124586.1 and a median of $155136.5 in 2023 frame the typical range for Change in Accured Expenses.
- The widest YoY moves for Change in Accured Expenses: up 645.19% in 2023, down 7233.52% in 2023.
- Over 4 years, Change in Accured Expenses stood at $16241.0 in 2022, then jumped by 645.19% to $121027.0 in 2023, then jumped by 49.56% to $181007.0 in 2024, then jumped by 196.53% to $536745.0 in 2025.
- According to Business Quant data, Change in Accured Expenses over the past three periods registered $536745.0, $138170.0, and $251028.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Neuraxis | 74.54 Mn | 66.21 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 536,745.00 |
| Dec 31, 2025 | 536,745.00 |
| Sep 30, 2025 | 138,170.00 |
| Sep 30, 2025 | 138,170.00 |
| Jun 30, 2025 | 251,028.00 |
| Jun 30, 2025 | 251,028.00 |
| Mar 31, 2025 | 156,784.00 |
| Mar 31, 2025 | 156,784.00 |
| Dec 31, 2024 | 181,007.00 |
| Dec 31, 2024 | 181,007.00 |
| Sep 30, 2024 | -238,822.00 |
| Sep 30, 2024 | -238,822.00 |
| Jun 30, 2024 | 592,114.00 |
| Jun 30, 2024 | 592,114.00 |
| Mar 31, 2024 | 415,394.00 |
| Mar 31, 2024 | 415,394.00 |
| Dec 31, 2023 | 121,027.00 |
| Dec 31, 2023 | 121,027.00 |
| Sep 30, 2023 | -755,499.00 |
| Sep 30, 2023 | -755,499.00 |